Page 17 - Lon Gsk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lon gsk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lon Gsk Today - Breaking & Trending Today

GlaxoSmithKline PLC and Sanofi reveal positive trial results for COVID-19 vaccine


The pair are targeting approval by the end of the year
GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi SA demonstrated strong immune responses in mid-stage trials.
The jab showed 95% to 100% seroconversion following a second injection in all age groups, with acceptable tolerability and with no safety concerns.
It prompted strong neutralising antibody levels that were comparable to those generated by natural infection, with higher levels observed in adults up to 59 years old.
Participants who previously contracted the virus experienced high antibody levels with the first dose, which the pharma company said suggests strong potential for development as a booster vaccine. ....

South Africa , South African , Big Caps , Harma Biotech , Glaxosmithkline Plc , Lon Gsk , பெரியது தொப்பிகள் ,

GSK, Sanofi eye late-stage trial of Covid-19 vaccine in coming weeks following positive update | 17 May 2021


17 May 2021 | 07:30am
StockMarketWire.com - Pharma giants GlaxoSmtihKline and Sanofi said they would move to a phase 3 trial of their Covid-19 vaccine in the coming weeks after a phase 2 trial showed strong rates of immune responses in all adult age groups.
The phase 2 study interim results show that the adjuvanted recombinant vaccine candidate triggered a strong immune response amongst adults of all age groups with 95% to 100% seroconversion rates and neutralizing antibodies that were comparable to those generated by natural infection, GSK said.
The phase 3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants, it added. ....

South Africa , South African , Glaxosmithkline Plc , Lon Gsk , Gsk L , கிளாக்சோஸ்மித்க்லைன் ப்ல் ,

FTSE sharply lower as UK eases restrictions | 17 May 2021


17 May 2021 | 12:01pm
StockMarketWire.com - Weakness in the mining and banking sectors and strength in sterling as the UK took the next step in its reopening helped put the FTSE 100 under pressure on Monday.
By midday the index was down 0.7% at 6,994.01.
Technical products and services provider Diploma rallied 7.3% to £29.50, having upgraded its annual outlook thanks to a boost from acquisitions, particularly WCW, and improved underlying trading.
Diploma s annual revenue was now expected to be slightly better than 40% ahead of the 2020 financial year, with an increase in its margin towards 19%.
Low-cost carrier Ryanair rose 0.6% even as it swung to a €815 million full-year loss after the pandemic hammered global travel markets. ....

United Kingdom , Hollywood Bowl , Diploma Plc , Lon Dplm , Dplm L , Lon Rya , Lon Vty , Dty L , Lon Gsk , Gsk L , Lon Pog , Enog L , ஒன்றுபட்டது கிஂக்டம் , ஹாலிவுட் கிண்ணம் , டிப்ளோமா ப்ல் ,